Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 151

1.

Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries.

Putrik P, Ramiro S, Guillemin F, Péntek M, Sivera F, Sokka T, de Wit M, Woolf AD, Zink A, Andersone D, Berghea F, Butrimiene I, Brouwer S, Cassar K, Charalambous P, Caporali R, Deseatnicova E, Damjanov NS, Finckh A, FitzGerald O, Gröndal G, Gobejishjvili N, Gluszko P, Hirsch M, Jovanovic I, Vencovský J, Janssens X, Keszei AP, Kovarova M, Kull M, Cunha Miranda L, Mayer M, Misevska-Percinkova S, Inanc N, Nadashkevich O, Petersson IF, Puolakka K, Rojkovich B, Radner H, Szabados F, Slobodin G, Shirinsky I, Soroka N, Sidiropoulos P, Shumnalieva R, Sokolovic S, Shukurova S, Tafaj A, Tomšič M, Uhlig T, Verstappen SMM, Boonen A.

Ann Rheum Dis. 2019 Aug 19. pii: annrheumdis-2019-215294. doi: 10.1136/annrheumdis-2019-215294. [Epub ahead of print]

PMID:
31427438
2.

Current status of use of big data and artificial intelligence in RMDs: a systematic literature review informing EULAR recommendations.

Kedra J, Radstake T, Pandit A, Baraliakos X, Berenbaum F, Finckh A, Fautrel B, Stamm TA, Gomez-Cabrero D, Pristipino C, Choquet R, Servy H, Stones S, Burmester G, Gossec L.

RMD Open. 2019 Jul 18;5(2):e001004. doi: 10.1136/rmdopen-2019-001004. eCollection 2019.

3.

EULAR points to consider for the use of big data in rheumatic and musculoskeletal diseases.

Gossec L, Kedra J, Servy H, Pandit A, Stones S, Berenbaum F, Finckh A, Baraliakos X, Stamm TA, Gomez-Cabrero D, Pristipino C, Choquet R, Burmester GR, Radstake TRDJ.

Ann Rheum Dis. 2019 Jun 22. pii: annrheumdis-2019-215694. doi: 10.1136/annrheumdis-2019-215694. [Epub ahead of print]

PMID:
31229952
4.

Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution.

Lauper K, Mongin D, Alpizar-Rodriguez D, Codreanu C, Iannone F, Kristianslund EK, Kvien TK, Pavelka K, Pombo-Suarez M, Santos MJ, Gabay C, Finckh A, Courvoisier DS.

Rheumatology (Oxford). 2019 Jun 17. pii: kez221. doi: 10.1093/rheumatology/kez221. [Epub ahead of print]

PMID:
31209481
5.

Preferences of Patients and At-risk Individuals for Preventive Approaches to Rheumatoid Arthritis.

Falahee M, Finckh A, Raza K, Harrison M.

Clin Ther. 2019 Jul;41(7):1346-1354. doi: 10.1016/j.clinthera.2019.04.015. Epub 2019 Jun 10.

PMID:
31196645
6.

Periodontal status correlates with anti-citrullinated protein antibodies in first-degree relatives of individuals with rheumatoid arthritis.

Loutan L, Alpizar-Rodriguez D, Courvoisier DS, Finckh A, Mombelli A, Giannopoulou C.

J Clin Periodontol. 2019 Jul;46(7):690-698. doi: 10.1111/jcpe.13117. Epub 2019 May 28.

PMID:
31025368
7.

Preventing rheumatoid arthritis: Preferences for and predicted uptake of preventive treatments among high risk individuals.

Harrison M, Spooner L, Bansback N, Milbers K, Koehn C, Shojania K, Finckh A, Hudson M.

PLoS One. 2019 Apr 25;14(4):e0216075. doi: 10.1371/journal.pone.0216075. eCollection 2019.

8.

The links of hepcidin and erythropoietin in the interplay of inflammation and iron deficiency in a large observational study of rheumatoid arthritis.

Scholz GA, Leichtle AB, Scherer A, Arndt U, Fiedler M, Aeberli D, Finckh A, Gabay C, Kyburz D, Villiger PM, Möller B.

Br J Haematol. 2019 Jul;186(1):101-112. doi: 10.1111/bjh.15895. Epub 2019 Apr 2.

PMID:
30941747
9.

2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis.

Ehlers L, Askling J, Bijlsma HW, Cid MC, Cutolo M, Dasgupta B, Dejaco C, Dixon WG, Feltelius N, Finckh A, Gilbert K, Mackie SL, Mahr A, Matteson EL, Neill L, Salvarani C, Schmidt WA, Strangfeld A, van Vollenhoven RF, Buttgereit F.

Ann Rheum Dis. 2019 Sep;78(9):1160-1166. doi: 10.1136/annrheumdis-2018-214755. Epub 2019 Mar 21.

PMID:
30898837
10.

[JAK inhibitors in the management of rheumatoid arthritis].

Finckh A.

Rev Med Suisse. 2019 Mar 6;15(641):528-532. French.

PMID:
30860322
11.

Prevotella copri in individuals at risk for rheumatoid arthritis.

Alpizar-Rodriguez D, Lesker TR, Gronow A, Gilbert B, Raemy E, Lamacchia C, Gabay C, Finckh A, Strowig T.

Ann Rheum Dis. 2019 May;78(5):590-593. doi: 10.1136/annrheumdis-2018-214514. Epub 2019 Feb 13.

PMID:
30760471
12.

Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider.

Unger J, Putrik P, Buttgereit F, Aletaha D, Bianchi G, Bijlsma JWJ, Boonen A, Cikes N, Dias JM, Falzon L, Finckh A, Gossec L, Kvien TK, Matteson EL, Sivera F, Stamm TA, Szekanecz Z, Wiek D, Zink A, Dejaco C, Ramiro S.

RMD Open. 2018 Dec 5;4(2):e000756. doi: 10.1136/rmdopen-2018-000756. eCollection 2018.

13.

EULAR 'points to consider' for the conduction of workforce requirement studies in rheumatology.

Dejaco C, Putrik P, Unger J, Aletaha D, Bianchi G, Bijlsma JW, Boonen A, Cikes N, Finckh A, Gossec L, Kvien TK, Madruga Dias J, Matteson EL, Sivera F, Stamm TA, Szekanecz Z, Wiek D, Zink A, Ramiro S, Buttgereit F.

RMD Open. 2018 Dec 5;4(2):e000780. doi: 10.1136/rmdopen-2018-000780. eCollection 2018.

14.

Role of reproductive and menopausal factors in functional and structural progression of rheumatoid arthritis: results from the SCQM cohort.

Alpizar-Rodriguez D, Förger F, Courvoisier DS, Gabay C, Finckh A.

Rheumatology (Oxford). 2019 Mar 1;58(3):432-440. doi: 10.1093/rheumatology/key311.

PMID:
30380120
15.

Towards standardized patient reported physical function outcome reporting: linking ten commonly used questionnaires to a common metric.

Oude Voshaar MAH, Vonkeman HE, Courvoisier D, Finckh A, Gossec L, Leung YY, Michaud K, Pinheiro G, Soriano E, Wulfraat N, Zink A, van de Laar MAFJ.

Qual Life Res. 2019 Jan;28(1):187-197. doi: 10.1007/s11136-018-2007-0. Epub 2018 Oct 13.

16.

Glucocorticoid injections for greater trochanteric pain syndrome: a randomised double-blind placebo-controlled (GLUTEAL) trial.

Nissen MJ, Brulhart L, Faundez A, Finckh A, Courvoisier DS, Genevay S.

Clin Rheumatol. 2019 Mar;38(3):647-655. doi: 10.1007/s10067-018-4309-6. Epub 2018 Sep 28.

PMID:
30267357
17.

Prediction of Real-World Drug Effectiveness Prelaunch: Case Study in Rheumatoid Arthritis.

Didden EM, Ruffieux Y, Hummel N, Efthimiou O, Reichenbach S, Gsteiger S, Finckh A, Fletcher C, Salanti G, Egger M; IMI GetReal Work Package 4.

Med Decis Making. 2018 Aug;38(6):719-729. doi: 10.1177/0272989X18775975.

PMID:
30074882
18.

Initial validation and results of the Symptoms in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire: a EULAR project.

van Beers-Tas MH, Ter Wee MM, van Tuyl LH, Maat B, Hoogland W, Hensvold AH, Catrina AI, Mosor E, Stamm TA, Finckh A, Courvoisier DS, Filer A, Sahbudin I, Stack RJ, Raza K, van Schaardenburg D.

RMD Open. 2018 May 21;4(1):e000641. doi: 10.1136/rmdopen-2017-000641. eCollection 2018.

19.

Incidence and Prevalence of Major Adverse Cardiovascular Events in Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis.

Lauper K, Courvoisier DS, Chevallier P, Finckh A, Gabay C.

Arthritis Care Res (Hoboken). 2018 Dec;70(12):1756-1763. doi: 10.1002/acr.23567.

PMID:
29609199
20.

[Microbiota and inflammatory rheumatisms].

Jarlborg M, Alpizar-Rodriguez D, Baillet A, Finckh A.

Rev Med Suisse. 2018 Mar 7;14(597):538-541. French.

PMID:
29512952
21.

Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort.

Hebeisen M, Neuenschwander R, Scherer A, Exer P, Weber U, Tamborrini G, Micheroli R, Wildi LM, Zufferey P, Nissen MJ, Villiger PM, Bernhard J, Finckh A, van der Horst-Bruinsma IE, Sieper J, Landewé R, van der Heijde D, Ciurea A; rheumatologists of the Swiss Clinical Quality Management Program.

J Rheumatol. 2018 Apr;45(4):506-512. doi: 10.3899/jrheum.170166. Epub 2018 Feb 15.

PMID:
29449504
22.

Chagas disease and systemic autoimmune diseases among Bolivian patients in Switzerland.

Jackson Y, Pula DVM, Finckh A, Chizzolini C, Chappuis F.

Mem Inst Oswaldo Cruz. 2018 Feb 5;113(4):e170383. doi: 10.1590/0074-02760170383.

23.

2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis.

Radner H, Chatzidionysiou K, Nikiphorou E, Gossec L, Hyrich KL, Zabalan C, van Eijk-Hustings Y, Williamson PR, Balanescu A, Burmester GR, Carmona L, Dougados M, Finckh A, Haugeberg G, Hetland ML, Oliver S, Porter D, Raza K, Ryan P, Santos MJ, van der Helm-van Mil A, van Riel P, von Krause G, Zavada J, Dixon WG, Askling J.

Ann Rheum Dis. 2018 Apr;77(4):476-479. doi: 10.1136/annrheumdis-2017-212256. Epub 2018 Jan 4.

PMID:
29301783
24.

Lessons learned from rheumatoid arthritis registries.

Finckh A, Courvoisier D.

Joint Bone Spine. 2018 May;85(3):271-274. doi: 10.1016/j.jbspin.2017.12.005. Epub 2017 Dec 12. No abstract available.

PMID:
29246533
25.

Low Hemoglobin and Radiographic Damage Progression in Early Rheumatoid Arthritis: Secondary Analysis From a Phase III Trial.

Möller B, Everts-Graber J, Florentinus S, Li Y, Kupper H, Finckh A.

Arthritis Care Res (Hoboken). 2018 Jun;70(6):861-868. doi: 10.1002/acr.23427. Epub 2018 Apr 25.

26.

Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis.

Alpizar-Rodriguez D, Mueller RB, Möller B, Dudler J, Ciurea A, Zufferey P, Kyburz D, Walker UA, von Mühlenen I, Roux-Lombard P, Mahler M, Lamacchia C, Courvoisier DS, Gabay C, Finckh A.

Rheumatology (Oxford). 2017 Sep 1;56(9):1579-1585. doi: 10.1093/rheumatology/kex239.

PMID:
28859327
27.

Value of Biomarkers in the Prevention of Rheumatoid Arthritis.

Finckh A, Alpizar-Rodriguez D, Roux-Lombard P.

Clin Pharmacol Ther. 2017 Oct;102(4):585-587. doi: 10.1002/cpt.727. Epub 2017 Jul 19.

PMID:
28722123
28.

Prise en charge d’une polyarthrite débutante.

Finckh A.

Rev Med Suisse. 2017 Jan 25;13(547):192-195. French. No abstract available.

PMID:
28703971
29.

Environmental factors and hormones in the development of rheumatoid arthritis.

Alpízar-Rodríguez D, Finckh A.

Semin Immunopathol. 2017 Jun;39(4):461-468. doi: 10.1007/s00281-017-0624-2. Epub 2017 Apr 27. Review.

PMID:
28451785
30.

New viral outbreaks: time for rheumatologists to get involved?: Chronic arthralgias and viral infections.

Finckh A, Alpizar-Rodriguez D, Lazarou I.

Rheumatology (Oxford). 2017 Dec 1;56(12):2046-2047. doi: 10.1093/rheumatology/kex177. No abstract available.

PMID:
28449075
31.

Presence of IL-17 in synovial fluid identifies a potential inflammatory osteoarthritic phenotype.

Snelling SJ, Bas S, Puskas GJ, Dakin SG, Suva D, Finckh A, Gabay C, Hoffmeyer P, Carr AJ, Lübbeke A.

PLoS One. 2017 Apr 11;12(4):e0175109. doi: 10.1371/journal.pone.0175109. eCollection 2017.

32.

Differential impact of systemic lupus erythematosus and rheumatoid arthritis on health-related quality of life.

Chaigne B, Finckh A, Alpizar-Rodriguez D, Courvoisier D, Ribi C, Chizzolini C; Swiss Clinical Quality Management Program For Rheumatoid Arthritis; Swiss Systemic Lupus Erythematosus Cohort Study Group.

Qual Life Res. 2017 Jul;26(7):1767-1775. doi: 10.1007/s11136-017-1534-4. Epub 2017 Mar 11.

PMID:
28285445
33.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D.

Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. Epub 2017 Mar 6. Review.

34.

The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis.

Alpizar-Rodriguez D, Brulhart L, Mueller RB, Möller B, Dudler J, Ciurea A, Walker UA, Von Mühlenen I, Kyburz D, Zufferey P, Mahler M, Bas S, Gascon D, Lamacchia C, Roux-Lombard P, Lauper K, Nissen MJ, Courvoisier DS, Gabay C, Finckh A.

Clin Rheumatol. 2017 Mar;36(3):677-682. doi: 10.1007/s10067-017-3547-3. Epub 2017 Jan 21.

PMID:
28110385
35.

Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA).

Iannone F, Courvoisier DS, Gottenberg JE, Hernandez MV, Lie E, Canhão H, Pavelka K, Hetland ML, Turesson C, Mariette X, Choquette D, Finckh A.

Clin Rheumatol. 2017 Apr;36(4):773-779. doi: 10.1007/s10067-016-3505-5. Epub 2016 Dec 14.

PMID:
27966068
36.

Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM).

Mueller RB, Reshiti N, Kaegi T, Finckh A, Haile SR, Schulze-Koops H, Schiff M, Spaeth M, von Kempis J; SCQM physicians.

Clin Rheumatol. 2017 Jan;36(1):59-66. doi: 10.1007/s10067-016-3468-6. Epub 2016 Nov 12.

37.

The role of female hormonal factors in the development of rheumatoid arthritis.

Alpízar-Rodríguez D, Pluchino N, Canny G, Gabay C, Finckh A.

Rheumatology (Oxford). 2017 Aug 1;56(8):1254-1263. doi: 10.1093/rheumatology/kew318. Review.

PMID:
27686101
38.

Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study.

Courvoisier DS, Alpizar-Rodriguez D, Gottenberg JE, Hernandez MV, Iannone F, Lie E, Santos MJ, Pavelka K, Turesson C, Mariette X, Choquette D, Hetland ML, Finckh A.

EBioMedicine. 2016 Sep;11:302-306. doi: 10.1016/j.ebiom.2016.08.024. Epub 2016 Aug 18.

39.

Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis.

Choy E, Aletaha D, Behrens F, Finckh A, Gomez-Reino J, Gottenberg JE, Schuch F, Rubbert-Roth A.

Rheumatology (Oxford). 2017 May 1;56(5):689-697. doi: 10.1093/rheumatology/kew271. Review.

PMID:
27550301
40.

Preventive Treatments for Rheumatoid Arthritis: Issues Regarding Patient Preferences.

Finckh A, Escher M, Liang MH, Bansback N.

Curr Rheumatol Rep. 2016 Aug;18(8):51. doi: 10.1007/s11926-016-0598-4. Review.

PMID:
27402108
41.

Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers.

Mercer LK, Askling J, Raaschou P, Dixon WG, Dreyer L, Hetland ML, Strangfeld A, Zink A, Mariette X, Finckh A, Canhao H, Iannone F, Zavada J, Morel J, Gottenberg JE, Hyrich KL, Listing J.

Ann Rheum Dis. 2017 Feb;76(2):386-391. doi: 10.1136/annrheumdis-2016-209285. Epub 2016 Jun 15.

42.

[Reactive arthritis: inflammation or true infection?].

Finckh A.

Rev Med Suisse. 2016 Mar 9;12(509):503-6. French.

PMID:
27089639
43.

The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis.

Nissen MJ, Ciurea A, Bernhard J, Tamborrini G, Mueller R, Weiss B, Toniolo M, Exer P, Gabay C, Finckh A; physicians of the Swiss Clinical Quality Management Cohort.

Arthritis Rheumatol. 2016 Sep;68(9):2141-50. doi: 10.1002/art.39691.

44.

Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative.

Baillet A, Gossec L, Carmona L, Wit Md, van Eijk-Hustings Y, Bertheussen H, Alison K, Toft M, Kouloumas M, Ferreira RJ, Oliver S, Rubbert-Roth A, van Assen S, Dixon WG, Finckh A, Zink A, Kremer J, Kvien TK, Nurmohamed M, van der Heijde D, Dougados M.

Ann Rheum Dis. 2016 Jun;75(6):965-73. doi: 10.1136/annrheumdis-2016-209233. Epub 2016 Mar 16. Review.

45.

Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis.

Gottenberg JE, Courvoisier DS, Hernandez MV, Iannone F, Lie E, Canhão H, Pavelka K, Hetland ML, Turesson C, Mariette X, Finckh A.

Arthritis Rheumatol. 2016 Jun;68(6):1346-52. doi: 10.1002/art.39595.

46.

Low pre-treatment B-cell counts are not a risk factor of infection in patients treated with rituximab for autoimmune diseases: An observational study.

Lazarou I, Finckh A, Fischer L, Ribi C, Gascon D, Seebach JD, Guerne PA.

Joint Bone Spine. 2016 Mar;83(2):191-7. doi: 10.1016/j.jbspin.2015.05.012. Epub 2015 Dec 8.

PMID:
26677998
47.

The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries.

Finckh A, Neto D, Iannone F, Loza E, Lie E, van Riel P, Hetland ML, Pavelka K, Gottenberg JE, Canhão H, Mariette X, Turesson C.

RMD Open. 2015 Apr 30;1(1):e000040. doi: 10.1136/rmdopen-2014-000040. eCollection 2015.

48.

The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.

Huttner A, Dayer JA, Yerly S, Combescure C, Auderset F, Desmeules J, Eickmann M, Finckh A, Goncalves AR, Hooper JW, Kaya G, Krähling V, Kwilas S, Lemaître B, Matthey A, Silvera P, Becker S, Fast PE, Moorthy V, Kieny MP, Kaiser L, Siegrist CA; VSV-Ebola Consortium.

Lancet Infect Dis. 2015 Oct;15(10):1156-1166. doi: 10.1016/S1473-3099(15)00154-1. Epub 2015 Aug 4.

49.

Inflammatory Articular Disease in Patients with Inflammatory Bowel Disease: Result of the Swiss IBD Cohort Study.

Ditisheim S, Fournier N, Juillerat P, Pittet V, Michetti P, Gabay C, Finckh A; Swiss IBD Cohort Study Group.

Inflamm Bowel Dis. 2015 Nov;21(11):2598-604. doi: 10.1097/MIB.0000000000000548.

Supplemental Content

Loading ...
Support Center